Pharma channel feed

Nek­tar sues Lil­ly, claim­ing its in­ter­est in biotech’s au­toim­mune drug ‘waned dra­mat­i­cal­ly’ af­ter buy­ing Der­mi­ra

Last year
Law

J&J inks an­oth­er Ste­lara biosim­i­lar set­tle­ment, push­ing Formy­con’s can­di­date in­to po­ten­tial 2025 launch

Last year

Hos­pi­tal groups ask Con­gress to re­form 340B pro­gram, crack down on con­tract phar­ma­cy re­stric­tions

Last year
FDA+

Vista­gen's pos­i­tive PhI­II for so­cial anx­i­ety nasal spray push­es stock price up 1,000+%

Last year

Vi­a­tris plans for Ozem­pic, We­govy gener­ics amid law­suit from No­vo Nordisk over We­govy

Last year

Ab­b­Vie dou­bles down on cor­po­rate aware­ness ef­forts in lat­est so­cial and dig­i­tal cam­paign

Last year
Marketing

Sage sug­gests job and pipeline cuts af­ter FDA re­jec­tion of ma­jor de­pres­sion pill

Last year
People
FDA+

Ac­er­a­gen to pull out of Nas­daq and liq­ui­date as­sets, end­ing tu­mul­tuous jour­ney for Idera Phar­ma

Last year
R&D

FDA ap­proves sec­ond ge­o­graph­ic at­ro­phy drug but caps use pe­ri­od, as Astel­las’ Iver­ic looks to spar with Apel­lis

Last year
FDA+

Up­dat­ed: FDA ap­proves Bio­gen and Sage's pill for post­par­tum de­pres­sion, but re­jects use in ma­jor de­pres­sion

Last year
R&D

Te­va agrees ‘in prin­ci­ple’ to $175M opi­oid set­tle­ment to hos­pi­tals and health sys­tems

Last year
Law

New FDA guid­ance gives man­u­fac­tur­ers lim­its for ni­trosamines

Last year
FDA+
Manufacturing

CDC vac­cine com­mit­tee votes unan­i­mous­ly to rec­om­mend Sanofi and As­traZeneca's RSV im­mu­niza­tion for ba­bies

Last year
Marketing

BAR­DA or­ders more small­pox and mpox vac­cines from Bavar­i­an Nordic

Last year
Deals
Manufacturing

Pfiz­er places a dozen prod­ucts on emer­gency or­der af­ter tor­na­do dam­age at North Car­oli­na plant

Last year

De­tails emerge on Cidara/J&J in­fluen­za part­ner­ship, with a count­down on next steps

Last year
Deals

Gala­pa­gos seeks 's­trate­gic op­tion­s' for Jy­s­e­le­ca as JAK in­hibitor sales dis­ap­point again

Last year

Gilead touts speed­i­er-than-ex­pect­ed pipeline ad­vances amid sol­id Q2 drug sales, ex­cept Covid-19 treat­ment Vek­lury

Last year

Cor­rect­ed: Ken­tucky takes PBMs to court over 'outra­geous' in­sulin prices

Last year
Law

Genen­tech up­dates spinal mus­cu­lar at­ro­phy ef­fort with new de­sign, so­cial me­dia and ‘Re­al Talk’

Last year
Marketing

FDA ex­pands Mer­ck­'s Ebo­la vac­cine ap­proval to chil­dren one year and old­er

Last year

FDA’s de­cen­tral­ized tri­al guid­ance: PhRMA, Mayo Clin­ic and oth­ers seek tweaks

Last year
FDA+

Re­gen­eron plans for quick re­de­ci­sion on CRL for high­er dose of Eylea

Last year
FDA+
Manufacturing

Up­dat­ed: Mod­er­na ramps up R&D spend in RSV, flu and cy­tomegalovirus in Q2

Last year
First page Previous page 110111112113114115116 Next page Last page
A service from the Financial Times